Anemarsaponin E is extracted from Anemarrhena asphodeloides Bunge and has anti-inflammatory activity.

Angiotensin (1-7) (Ang-(1-7)) is an active heptapeptide of the Renin-angiotensin system (RAS), inhibits purified canine angiotensin converting enzyme (ACE) activity with IC50 of 0.65 uM.

Angiotensin II human is a peptide hormone that causes vasoconstriction and a subsequent increase in blood pressure.

Anguizole is a HCV NS4B inhibitor targeting second amphipathic helix of NS4B (NS4B-AH2), blocks genotype 1b HCV replication with EC50 of 310 nM.

Anidulafungin

Aniracetam(Ro 13-5057) is a nootropics and neuroprotective drug, which is selectively modulates the AMPA receptor and nAChR.

Anle138b is a novel oligomer modulator.

Maytansinol inhibits microtubule assembly and induces microtubule disassembly in vitro. Target: Microtubule/Tubulin in vitro: Maytansinol disrupts the mitotic spindle and prevents mitotic exit in Drosophila. Maytansinol reduces the growth and/or survival of HCT116 cells in a dose-dependent manner and that the effect was more severe for p53+/+ than for p53-/- cells at both low and high doses. Maytansinol inhibits the growth of HCT116 human colon cancer cells. Maytansinol induces apoptosis in imaginal discs of wild-type larvae but not p53 mutant larvae. This parallels the finding in human HCT116 cells, in which Maytansinol was more effective when p53 was present, at least at some doses. Maytansinol induces apoptosis in imaginal discs of wild-type larvae but not p53 mutant larvae at 24 hours after exposure to drug.

Ansamitocin P-3, a potent anti-tumor maytansinoid found in Actinosynnema pretiosum, is a maytansine analog which displays potent cytotoxicity against the human solid tumor cell lines A-549 and HT-29.

ANT431 is a novel potent metallo-β-lactamase (MBL) inhibitor with IC50 of 290 nM and 195 nM for NDM-1 and VIM-2, shows a comparatively weak inhibitor of VIM-1 and IMP-1 (Ki of 14.6 and 4.15 uM, respectively).

ANT431 sodium is a novel, highly water-soluble metallo-β-lactamase (MBL) inhibitor with IC50 of 290 nM and 195 nM for NDM-1 and VIM-2, shows a comparatively weak inhibitor of VIM-1 and IMP-1 (Ki of 14.6 and 4.15 uM, respectively).

antifungal.

Antimalarial compound 49c is a potent antimalarial peptidomimetic inhibitor originally developed against Plasmepsin II selectively targets TgASP3, PfPMIX, and PfPMX, shows very potent antimalarial effects only after 72 h of treatment with IC50 of 0.6 nM.

Antimycin A is an inhibitor of cellular respiration, specifically oxidative phosphorylation, binds to the Qi site of cytochrome c reductase, disrupts the Q-cycle of enzyme turn over.

Antipyrine is an analgesic and antipyretic agent

ANY1 (FosA inhibitor ANY1) is a small molecule active site inhibitor of FosA (metal-dependent glutathione S-transferase) with IC50 of 5.1 uM (K. pneumoniae FosA).

AOH1160 is a potent, first-in-class, orally available small molecule inhibitor of Proliferating cell nuclear antigen (PCNA).

AP14145 (AP-14145) is a potent, selective negative allosteric modulator of KCa2.2 and KCa2.3 with equal potency (IC50=1.1±0.3 uM).

AP1867 is a synthetic FKBP12F36V-directed ligand.

AP1903 (Rimiducid, AP-1903) is a potent, specific synthetic ligand of FKBP Phe36Val mutant (F36V-FKBP) with binding IC50 of 1.8 nM.

AP219 is a control compound for AP39, containing the triphenylphosphonium scaffold but lacking the H2S-releasing portion.

AP24534 is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM, respectively.

ALK-IN-1 (Brigatinib analog) is a potent and selective active inhibitor of anaplastic lymphoma kinase(ALK), Patent US20140066406 A1.

APA modulator T4 is a small modulator of alternative polyadenylation (APA) with IC50 of 2.1 uM in reporter assays, modulates endogenous APA via nonkinase-mediated pathways and promotes distal-to-proximal (DtoP) APA usage in multiple transcripts.

APA modulator T5 is a small modulator of alternative polyadenylation (APA), modulates endogenous APA via nonkinase-mediated pathways and promotes distal-to-proximal (DtoP) APA usage in multiple transcripts.

Apararenone (MT-3995) is a novel potent, selective non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis..

Apatinib (YN968D1) is an orally bioavailable, selective VEGFR2 inhibitor with IC50 of 1 nM.

Apatinib is an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities.

Apcin is a cell-permeable, small molecule anaphase-promoting complex/cyclosome (APC/C) inhibitor, which binds to Cdc20 and competitively inhibits the ubiquitylation of D-box-containing substrates.

APD-371 (APD371, Olorinab) is a potent, selective and orally available CB2 agonist with EC50 of 6.2 nM; displays no activity against CB1 receptors (EC50>10 uM); exhibits activity in rat model of osteoarthritis pain.

APD597(JNJ-38431055) is a GPR119 agonist intended for the treatment of type 2 diabetes, with EC50 of 46 nM for hGPR119.

APD916 is a potent and selective antagonist of the H3 receptor with Ki of 0.7 nM for rH3R.

apelin receptor.

Apicidin (OSI 2040) is a fungal metabolite that exhibits potent, broad spectrum antiprotozoal activity in vitro, potently inhibits HDAC with IC50 of 0.7 nM in an enzyme activity assay.

Apilimod(STA 5326) is a potent IL-12/IL-23 inhibitor, IL-12 production in cultures of IFN-r/LPS–stimulated human PBMCs is strongly inhibited by STA-5326 with an IC50 of 10 nM.

Apilimod(STA 5326) mesylate is a potent IL-12/IL-23 inhibitor, IL-12 production in cultures of IFN-r/LPS–stimulated human PBMCs is strongly inhibited by STA-5326 with an IC50 of 10 nM.

Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively.

Aplaviroc (GSK-873140.

Aplaviroc, also known as AK-602; GW-873140; GW873140A; ONO-4128, is a CCR5 entry inhibitor for the potential treatment of HIV infection. Aplaviroc (GW873140) binds specifically to human cellular CC chemokine receptor 5 (CCR5) and demonstrates potent anti-human immunodeficiency virus activity in vitro in the subnanomolar range. In vitro studies show that aplaviroc selectively inhibits the binding of a particular monoclonal antibody, 45531, to CCR5.

APO866 effectively inhibits nicotinamide phosphoribosyltransferase (NMPRTase) with IC50 of 0.09 nM.

Apogossypol (NSC 736630) is a Bcl-2 family antagonist that binds to Bcl-XL, Bcl-2 and Bcl-xL with IC50 of 2.6, 2.8 and 3.69 uM, respectively.

Apomorphine hydrochloride hemihydrate is a non-selective dopamine agonist which activates both D1-likeand D2-like receptors, with some preference for the latter subtypes..

Apoptosis Activator 2 activates caspases in a cytochrome c-dependent manner and induces apoptosis in tumor cells.

Apoptozole is an inhibitor of heat shock protein 70 (Hsp70; 65% inhibition at 200 μM) that acts by blocking its ATPase activity.

Apremilast(CC10004) is a novel small molecule inhibitor of PDE4 with an IC50 value of 74 nM.

Apricitabine is a novel nucleoside reverse transcriptase inhibitor for the treatment of HIV infection that is refractory to existing drugs

Aprocitentan (ACT-132577) is the major and pharmacologically active metabolite of macitentan, which is dual ETA/ETB antagonist designed for tissue targeting.

Aprotinin is a serine protease inhibitor isolated from bovine lung which inhibits trypsin and chymotrypsin with Ki values of 0.06 pM and 9 nM, respectively.

APS-2-79 is a novel modulator of KSR-dependent MAPK signalling,KSR2,IC50=120 nM

APS-2-79 is a novel modulator of KSR-dependent MAPK signalling,KSR2,IC50=120 nM

APS-3-77 is the negative binder of KSR2.

APTO-253 is a novel small molecule with potent anti-tumor activity in cancer cells via induction of the gene that expresses the Krüppel-like factor 4 (KLF4) master transcription factor, leading to cell cycle inhibition and programmed cell death.

APTO-253 is a small molecule inducer of KLF4, stabilizes G-quadruplex DNA and reduces MYC mRNA expression and protein levels.

APX001 (APX 001A;E1210) is a novel broad-spectrum antifungal agent that inhibits the fungal protein Gwt1, demonstrates significantly acitive MIC50 and MIC90 values of 0.004 and 0.031 ug/ml (16 strains of C. auris).

APX-115 (Ewha 18278) is a first-in-class, orally active, pan-NADPH oxidase (Nox) inhibitor with Ki of 1.08, 0.57, 0.63 nM for Nox1, Nox2, and Nox4, respectively.

APX2009 (APX-2009) is a novel potent inhibitor of reduction-oxidation factor 1-apurinic/apyrimidinic endonuclease 1 (Ref-1/APE1) with IC50 of 0.45 uM for redox EMSA inhibition.

APX2014 (APX-2014) is a novel potent inhibitor of reduction-oxidation factor 1-apurinic/apyrimidinic endonuclease 1 (Ref-1/APE1) with IC50 of 0.2 uM for redox EMSA inhibition.

APY0201 is a potent, highly selective PIKfyve kinase inhibitor.

APY29 is an allosteric modulator of IRE1α; inhibits IRE1α autophosphorylation (IC50 = 280 nM) and activates IRE1α RNase activity.

AQ-101 is a novel small-molecule anthraquinone analog that induces MDM2 protein degradation (Kd=0.37 uM) through a self-ubiquitination and proteasome-mediated mechanism, leading to activation of p53.

AQ-13 dihydrochloride is an aminoquinoline antimalarial drug that is effective against chloroquine-resistant strains of Plasmodium falciparum.

AQW-051 is a novel, potent and selective, orally bioavailable, brain-penetrant α7 nAChR partial agonist with pKd of 7.56.

AQX 1125 (Rosiptor) is a specific, orally bioavailable SHIP1 activator.

AR03 (AR-03, AR 03, Ape1 repair inhibitor 03) is a novel small molecule inhibitor of DNA repair protein apurinic/apyrimidinic endonuclease 1 (APE1) endonuclease activity with IC50 of 5 uM.

AR231453 is a potent and selective small molecule agonist of GPR119 that enhances glucose-dependent insulin secretion and glucagon-like peptide 1 (GLP-1) release; Antidiabetic agent.

AR7 is a retinoic acid receptor α (RARα) antagonist.

ARA-290 (Cibinetide) is a non-erythropoietic erythropoietin (EPO) derivative.

Ara-G (9-β-D-Arabinofuranosyl guanine) is an inducer of apoptosis, inhibitor of DNA synthesis, an antimetabolite, and antineoplastic.

Umifenovir is currently being investigated as a potential treatment and prophylactic agent for COVID-19 caused by SARS-CoV2 infections in combination with both currently available and investigational HIV therapies. Arbidol hydrochloride (Umifenovir hydroc

AR-C102222 is a potent, selective iNOS inhibitor with IC50 of 35 nM, dislapys 3,000-fold and 20-fold selectivity over eNOS and nNOS respectively.

AR-C155858 is a potent monocarboxylate transporter MCT1 and MCT2 with Ki of 2.3 nM and <10 nM, displays no activity at MCT4.

Arctigenin is an extract from A. lappa, a burdock plant traditionally used in Japanese Kampo medicine for its antioxidant, anti-inflammatory,

Arctiin, a plant lignan that can be extracted from the Arctium lappa (burdock) seeds, is a possible environmental endocrine disruptor compounds and have been shown to influence sex hormone metabolism as well as protein synthesis, steroid biosynthesis.

Arg-AMS is a potent nanomolar inhibitor of arginyl tRNA synthetase, which displays tightly bound inhibitory characteristics for the A-domains in non-ribosomal peptide synthetases (NRPS) enzymes.

Argatroban

Argatroban monohydrate is a direct, selective thrombin inhibitor.

Arg-Gly-Asp-Ser(RGDS peptide) is an integrin binding sequence that inhibits integrin receptor function; decreases systemic inflammation via inhibition of collagen-triggered activation of leukocytes and attenuates expression of inflammatory cytokines, iNOS

Arglabin is a sesquiterpene gamma-lactone is isolated from Artemisia glabella; anticancer natural compound.

AR-HO47108 is a potent, selective acid pump antagonist (potassium-competitive acid blocker or P-CAB) that reversiblely inhibits gastric H+/K+-ATPase with pIC50 of 7.0.

Aripiprazole(Abilify) is a human 5-HT1A receptor partial agonist with a Ki of 4.2 nM.

ARM390 is a non-peptidic, low-internalizing δ-selective opioid receptor agonist.

ARN077 is the first potent, selective N-acylethanolamine acid amidase (NAAA) inhibitor with IC50 of 7 nM on both rat NAAA and human NAAA.

ARN14494 (ARN-14494) is a potent, small molecule serine palmitoyltransferase (SPT) inhibitor with IC50 of 27.3 nM.

ARN19874 (ARN-19874) is the first selective, cell-active inhibitor of N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD) with IC50 of 33.7 uM.

ARN2966 is a potent post-transcriptional modulator of APP expression; reduces expression of APP with resultant lower production of Aβ.

ARN-3236 is potent, orally active and selective SIK2 inhibitor. ARN-3236 inhibited the growth of 10 ovarian cancer cell lines at an IC50 of 0.8 to 2.6 μmol/L.

ARN-3261 is a potent, selective, orally available salt inducible kinase SIK2 and SIK3 inhibitor with IC50 of 11 nM and 19 nM, respectively.

ARN-509 is a selective and competitive androgen receptor inhibitor with IC50 of 16 nM, useful for prostate cancer treatment.

ARN726 is a potent, selective, orally bioavailable N-acylethanolamine acid amidase (NAAA) inhibitor with IC50 of 63 nM (r-NAAA) and 27 nM (h-NAAA).

ARP101 (ARP-101) is a selective MMP-2 inhibitor, induces autophagy-associated cell death in cancer cells.

ARQ 092 is an oral activie, potent and selective AKT inhibitor with IC50 values: 5.0 nM (AKT1); 4.5 nM (AKT2); 16 nM (AKT3).

ARQ 621 is an allosteric, and selective Eg5 mitotic motor protein inhibitor. Phase 1.

ARQ-531 is a potent, reversible, orally available inhibitor of both wild type and C481S-mutant BTK kinase with IC50 of 0.85 and 0.39 nM,

ARRY-334543 is a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases.

ARRY-502 is an orally bioavailable, potent and selective antagonist of the prostaglandin D2 receptor (CRTh2) for treatment of mild to moderate Th2-driven asthma..

ARRY-520 is a synthetic, small molecule kinesin spindle protein (KSP) inhibitor with IC50 of 6 nM.

ARRY-520 R enantiomer is the R form of ARRY-520, which is a synthetic, small molecule kinesin spindle protein (KSP) inhibitor with IC50 of 6 nM.

ARS-1323 is a novel inhibitor of mutant K-ras G12C.

ARS-1620 is a covalent compound with high potency and selectivity for KRAS-G12C.

ARS-1630 is the R-conformational atropisomer of ARS-1620, 1,000-fold less potent than ARS-1620 (1.2 ± 0.6 M-1s-1) and thus acts as a unique inactive control compound..

ARS-853 is a selective, covalent inhibitor of KRAS-G12C that inhibits mutant KRAS driven signaling by binding to the GDP bound oncoprotein and preventing activation.

Artefenomel (OZ439) is a novel, next-generation antimalarial ozonide that demonstrates high potentcy against P. falciparum in vitro and P. berghei in vivo (K1/NF54, IC50=2.0/3.2 nM)..

Arterolane (OZ277.

Articaine is a dental local anesthetic which contains an additional ester group that is metabolized by estearases in blood and tissue.

ARV-771 is a potent bromodomain and extra-terminal (BET) proteins degrader with Kd values of 4.7, 7.6, 7.6 nM against bromodomain 2, 3 and 4, respectively.

ARV-825 is a BRD4 Inhibitor based on PROTAC technology. ARV-825 binds to BD1 and BD2 of BRD4 with Kds of 90 and 28 nM, respectively.

Arylsulfonamide 64B (HIF inhibitor 64B) is a small molecule HIF pathway inhibitor, blocks hypoxia-induced expression of c-Met and CXCR4 and uveal melanoma (UM) cell migration.

AS 2553627 (AS2553627) is a novel potent, selective pan-JAK inhibitor with IC50 of 0.46, 0.30, 0.14 and 2.0 nM for JAK1, JAK2, JAK3 and TYK2, respectively.

AS 602801(Bentamapimod) is a novel, orally active inhibitor of JNK.

AS 8351 induces reprogramming of human fetal lung fibroblasts into functional cardiomyocytes, in combination with CHIR 99021, A83-01, BIX 01294, SC1, Y-27632, OAC2, SU 16f and JNJ 10198409.

AS-1269574 is a selective, orally available GPR119 agonist with EC50 of 2.5 uM in cell-based cAMP assays.

AS1517499 is a potent STAT6 inhibitor with IC50 of 21 nM.

AS1842856 is a potent and cell-permeable Foxo1 inhibitor with an IC50 of 30 nM.

AS1928370 (ASP8370) is a potent, selective, orally available TRPV1 antagonist with IC50 of 0.51 uM, shows no inhibitory effects on TRPV4, TRPA11, and TRPM8 at 10 uM.

AS-1949490 (AS1949490) is a potent, selective SHIP2 inhibitor with IC50 of 0.34/0.62 uM for mouse/human SHIP2.

AS2521780 is a potent, selective, orally bioavailable PKCθ inhibitor that inhibits combinant human PKCθ enzyme with IC50 of 0.48 nM, >30-fold higher than other PKC isoforms.

AS-252424 is a novel, potent and selective inhibitor of PI3Kγ with IC50 of 33 nM.

AS2541019 is a novel potent, selective, orally active PI3Kδ inhibitor with IC50 of 20.1 nM, >100-fold selectivity over other PI3K isoforms.

AS2677131(AS 2677131, AS-2677131) is a novel potent, oral PIKfyve inhibitor that selectively decreases c-Rel binding to gene promoters of IL-12p40 and IL-1β, regulates cytokine production through PIKfyve-c-Rel pathway ( IL-12p40 IC50=4 nM).

AS2717638 is an oral active lysophosphatidic acid receptor 5 (LPA5) antagonist in rodents. AS2717638 also significantly improves PGE2-, PGF2α-, and AMPA-induced allodynia.

AS-604850 is a selective, ATP-competitive PI3Kγ inhibitor with IC50 of 250 nM, over 80-fold selectivity for PI3Kγ than PI3Kδ/β, and 18-fold more selective for PI3Kγ than PI3Kα.

AS-605240 is a potent and selective inhibitor of PI 3-kinase γ (PI3Kγ) (IC50 = 8 nM). AS-605240 displays 30-fold selectivity over PI3Kδ and PI3Kβ and 7.5-fold selectivity over PI3Kα.

Asapiprant (BGE-175) is a potent and specific antagonist of human PGD2/PTGDR signaling with Ki of 0.44 nM. BGE-175 is currently in a Phase 2 clinical trial to test whether it can prevent disease progression and mortality in older patients hospitalized wit

Asciminib (ABL-001) is a potent and selective allosteric ABL1 inhibitor with IC50 of 0.25 nM in BCR–ABL1-transformed BaF3 cells.

ASC-J9, is antitumor agent. ASC-J9 suppresses castration-resistant prostate cancer growth via degradation of full-length and splice variant androgen receptors.

Ascomycin is an analog of tacrolimus with immunosuppressive, neurotrophic and antifungal activities.

Ascorbyl palmitate is an ester formed from ascorbic acid and palmitic acid creating a fat-soluble form of vitamin C.

Asimadoline (EMD-61753) is a drug which acts as a peripherally selective κ-opioid receptor (KOR) agonist.

ASK1-IN-1 is an apoptosis signal regulating kinase 1 (ASK1) inhibitor extracted from patent WO2016025474A1, Compound 4.

ASN-002 (Gusacitinib, ASN002) is a novel and potent dual inhibitor of SYK/JAK kinases with IC50 of 5-46 nM in biochemical assays.

ASP 7663 is a selective TRPA1 activator (EC50 values are ~0.5 μM in human, mouse and rat).

ASP3026 is a novel and selective inhibitor for ALK with IC50 of 3.5 nM.

ASP-4058 is a next-generation, selective and oral bioactive agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P1 and S1P5), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile.

ASP5878 is a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance.

ASP6432 (ASP-6432) is a potent and selective antagonist of LPA1 receptor, does-dependently inhibits LPA-stimulated increase in intracellular calcium ion with IC50 of 11 nM.

ASP7657 (ASP-7657) is a potent, selective, orally active prostaglandin EP4 receptor antagonist with Ki values of 6.02 nM and 2.21 nM for rat and human EP4 receptors, resepctively.

ASP9436 (ASP-9436) is a potent, selective brain penetrant and orally active phosphodiesterase 10A (PDE10A) inhibitor with IC50 of 8.0 nM, >420-fold selectivity over other PDE subtypes.

ASP-9521 is a potent, selective and orally available AKR1C3 inhibitor with an IC50 of 11 nM for human AKR1C3.

Aspacytarabine (Astarabine, BST236) is a cytarabine conjugate that shows anti-​neoplastic agents for inhibiting cancer cell growth. .

Asp-AMS, an analogue of aspartyl-adenylate, is an aspartyl-tRNA synthetase inhibitor and also a strong competitive inhibitor of the mitochondrial enzyme.

Aspartame

AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases.

AST-3424 (OBI-3424, TH-3424) is a first-in-class, novel prodrug that selectively targets cancers overexpressing the enzyme AKR1C3, OBI-3424 is a highly selective prodrug that is converted by AKR1C3 to a DNA alkylating agent.

Astaxanthin, a red dietary carotenoid isolated from Haematococcus pluvialis, is an inhibitor of PPARγ and a potent antioxidant with antiproliferative, neuroprotective and anti-inflammatory activity. Astaxanthin has potential in the treatment of various di

Astex ERK inhibitor X is a novel potent ERK1/2 inhibitor that inhibits ERK catalytic activity with IC50 of 3 nM in TRK kinase assays.

Astin C is a cyclopeptide isolated from the medicinal plant Aster tataricus, inhibits cGAS-STING signaling and the innate inflammatory responses triggered by cytosolic DNAs, inhibits intracellular DNA-induced Ifnb expression with IC50 of 3.42 and 10.83 uM

Astragaloside A, also known as astragaloside IV, is known to have diverse protective effects for the cardiovascular, immune, digestive, and nervous systems.

Astragaloside IV, an active component isolated from Astragalus membranaceus, suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells.

Astragaloside VI could activate EGFR/ERK signalling pathway to improve wound healing.

ASTX660 hydrochloride is a novel potent IAP antagonist that targets the BIR3 domain of cIAP1/2 and XIAP with IC50 of 12 nM and <40 nM.

ASTX660 is a novel potent IAP antagonist that targets the BIR3 domain of cIAP1/2 and XIAP with IC50 of 12 nM and <40 nM.

ASTX660 mesylate is a novel potent IAP antagonist that targets the BIR3 domain of cIAP1/2 and XIAP with IC50 of 12 nM and <40 nM.

Asunaprevir (BMS-650032) is a potent hepatitis C virus (HCV) NS3 protease inhibitor.

AT-090 is a novel potent, selective nociceptin/orphanin FQ receptor (NOP receptor) agonist with Ki of 5.61 nM.

AT-1002, a 6-mer synthetic peptide, is a tight junction regulator and absorption enhancer.

AT-101 is a BH3 mimetic known to be a potent inhibitor of antiapoptotic Bcl-2 family members.

AT-127 is a novel potent, selective nociceptin/orphanin FQ receptor (NOP receptor) agonist with Ki of 1.18 nM.

AT-130 is a potent inhibitor of HBV capsid assembly, inhibits wild-type HBV replication with IC50 of 2.4 uM.

AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity; AKT, p70S6K, PKA, ROCK, and SGK inhibitor.

AT13387 is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity.

AT-403 (AT403) is a potent, highly selective, nonpeptide NOP agonist with pEC50 of 9.45.

AT-406 (formerly known as SM-406) is an orally bioavailable potent IAP (inhibitor of apoptosis protein) of XIAP, cIAP1, and cIAP2 with Ki of 66.4 nM, 1.9 nM, and 5.1 nM, respectively.

AT-56 is a selective, competitive, and highly bioavailable inhibitor of lipocalin-type prostaglandin D synthase (L-PGDS) with a Ki value of 75 µM.

AT7519 is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM; less potent to CDK3 and little active to CDK7.

AT7519 is a novel multi-CDK inhibitor for CDK1/cyclin B, CDK2/Cyclin A, CDK3/Cyclin E, CDK4/Cyclin D1, CDK5/p35 and CDK6/Cyclin D3 with IC50 of 210 nM, 47 nM, 360 nM, 100 nM, 13 nM and 170 nM, respectively.

AT7519 trifluoroacetate is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM; less potent to CDK3 and little active to CDK7.

AT7867 Hcl is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively; little activity outside the AGC kinase family.

AT7867 is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively; little activity outside the AGC kinase family.

AT791 is a novel orally available, small molecule inhibitor of TLR7 and TLR9 with IC50 of 3.33 uM and 0.04 uM respectively, inhibits DNA-TLR9 interaction in vitro.

AT9283 is a small molecule a multi-targeted inhibitor with of 4, 1.2, 1.1 and approximate 3 nM for Bcr-Abl(T3151), Jak2 and Jak3, aurora A and B, respectively.

Atabecestat (JNJ-54861911, JNJ54861911) is a novel potent, oral beta-secretase (BACE) inhibitor for treatment of Alzheimer's Disease.

Ataciguat (HMR-1766) is a potent, specific soluble guanylate cyclase (sGC) activator with EC50 of 0.51 uM, preferentially activates the NO-insensitive heme-oxidized form of sGC.

Ataciguat (HMR-1766) is a potent, specific soluble guanylate cyclase (sGC) activator with EC50 of 0.51 uM, preferentially activates the NO-insensitive heme-oxidized form of sGC.

Atagabalin (PD 0200390) is a novel ligand of the voltage-dependent calcium channel (VDCC) α2δ subunit (1 and 2) for treatment for insomnia..

Atazanavir is a HIV protease inhibitor with Ki of 2.66 nM.

Atazanavir sulfate is a sulfate salt form of atazanavir that is an highly potent HIV-1 protease inhibitor.

ATB-346 is a novel hydrogen sulphide-releasing derivative of naproxen with markedly reduced toxicity.

Atenolol is a selective β1 receptor antagonist.

Atglistatin is a highly potent, selective and competitive inhibitor of adipose triglyceride lipase (ATGL) with an IC50 of ~0.7 μM for inhibition of lipolysis in vitro, but no toxicity up to a concentration of 50 μM.

ATH686 (ATH-686) is a potent and selective, second-generation inhibitor of mutant FLT3 protein kinase.

ATI-2341, pepducin targeting the C-X-C chemokine receptor type 4 (CXCR4), is an allosteric agonist activating the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization.

Atipamezole Hcl(MPV1248 Hcl) is an alpha-adrenoceptor antagonist with high affinity and selectivity for the alpha 2-receptor.

Atipamezole(MPV1248) is an alpha-adrenoceptor antagonist with high affinity and selectivity for the alpha 2-receptor.

Atiprimod (SKF 106615, Azaspirane) is a potent, orally bioavailable JAK2 inhibitor, inhibits phosphorylation of JAK2 and the downstream STAT3 and STAT5 pathways.

Atiprimod (SKF 106615, Azaspirane) is a potent, orally bioavailable JAK2 inhibitor, inhibits phosphorylation of JAK2 and the downstream STAT3 and STAT5 pathways.

ATM Inhibitor-1 is a highly potent, selective and orally active ATM inhibitor, with an IC50 of 0.7 nM, shows weak activity against mTOR (IC50, 21 μM), DNAPK (IC50, 2.8 μM), PI3Kα (IC50, 3.8 μM), PI3Kβ (IC50, 10.3 μM), PI3Kγ (IC50, 3 μM) and PI3Kδ (IC50, 0

ATM-3507 (ATM3507) is a small molecule inhibitor of Tpm3.1 tropomyosin isoform, disrupts Tpm3.1-containing microfilaments in SK-N-SH cells at 5 uM.

ATN-161 is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.

Atocalcitol

Atomoxetine ((R)-Tomoxetine.

Atomoxetine Hcl(LY 139603; Tomoxetine Hcl) is a potent and selective noradrenalin re-uptake inhibitor (Ki values are 5, 77 and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively).

Atorvastatin Calcium

Atovaquone is a medication used to treat or prevent for pneumocystis pneumonia, toxoplasmosis, malaria, and babesia.

ATP (Adenosine-Triphosphate)

ATR-101 (PD-132301, Nevanimibe) is a selective and potent inhibitor of ACAT1 with IC50 of 52 nM.

ATR-101 (PD-132301, Nevanimibe) is a selective and potent inhibitor of ACAT1 with IC50 of 52 nM.

Atractylenolide II has antiinflammatory activity, it can inhibit platelets activities and thrombus formation. Atractylenolide II has cytotoxic/apoptotic effects may via p38 activation ,ERK and Akt inactivation, p53 dependent, it also has antimelanoma effe

Atractylenolide III, a potential house dust mite control agent, has neuroprotection, gastroprotective, anti-cancer, and anti-inflammatory activities, it also may control immunological reactions by regulating the cellular functions of IL-6 in mast cells.

Atractylone has inhibitory effects on mast cell-mediated allergic reactions, it regulates the degranulation of mast cell, proves its potential in the treatment of mast cell-mediated allergic reactions.

Atracurium besylate is a non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.